Global Pharma Intermediates Technology Review: Routes, Compliance Cost and Maturity

Abstract

This report treats pharma intermediates as a technology and compliance question, not a market-sizing question. Three layers of competition overlap: synthetic routes are largely public knowledge, gaps in tonne-scale process capability are narrowing, and the layer still diverging is compliance engineering — whether a process is accepted by the site, passes customer audits and survives regulatory change control. The same molecule can be quoted 30% apart by two plants with near-identical certificates of analysis; the difference sits in that third layer.

It places six institutional estimates side by side (USD 14.0–187.73 bn for 2024/2025, more than an order of magnitude apart) and uses only the merchant-intermediate cluster of USD 36.60–45.45 bn: a primary anchor of USD 45.45 bn (2025) and a secondary anchor of USD 39.23 bn (2024). No averaging, no ultra-broad or narrow scopes. The 71 registered sources are graded A/B/C, 34 of 71 opened on the spot, and verification rates are reported against three separate denominators — nowhere does this report claim 100%.

Sources

• A 应急管理部《淘汰落后危险化学品安全生产工艺技术设备目录（第一批）》解读：列 12 项，其中工艺 4 项、设备 8 项。https://www.mem.gov.cn/gk/zcjd/202011/t20201127_372281.shtml（2026-11 访问）
• A 印度新闻局 PIB：2024–25 财年 API／原料药／中间体进口 43.48 亿美元，中国占 73.71%。https://www.pib.gov.in/PressReleasePage.aspx?PRID=2222528（2026-11 访问）
• B Mordor Intelligence《Pharmaceutical Intermediates Market》：2025 年 45.45 bn USD、2026–2031 CAGR 7.05%，本报告主锚。https://www.mordorintelligence.com/industry-reports/pharmaceutical-intermediates-market（2026-11 访问）
• B SkyQuest Technology《Pharmaceutical Intermediates Market》：2024 年 39.23 bn USD、CAGR 6.37%，本报告次锚。https://www.skyquestt.com/report/pharmaceutical-intermediates-market（2026-11 访问）
• B Future Market Insights：2025 年 36.60 bn USD、2026–2036 CAGR 4.5%。https://www.futuremarketinsights.com/reports/pharmaceutical-intermediates-market（2026-11 访问）
• B TSCI 经 GII 转载《醫藥中間體市場》：2025 年 43.64 bn USD、CAGR 5.61%。https://www.gii.tw/report/tsci1961090-pharmaceutical-intermediates-market-global.html（2026-11 访问）
• A ICH Q11 及 Q11 Q&A：起始物料自「重要结构片段」起并须论证；RSM 变更触发变更控制。https://admin.ich.org/sites/default/files/inline-files/Q11_Q&As_TrainingDeck_Final_2018_0522_0.pdf（2026-11 访问）
• A US EPA Presidential Green Chemistry Challenge 2010：西格列汀转氨酶路线较铑路线废物减少 19%。https://www.epa.gov/greenchemistry/presidential-green-chemistry-challenge-2010-greener-reaction-conditions-award（2026-11 访问）
• A EFPIA《Medicines Manufacturing in Figures 2024》：欧洲（EU27＋瑞士＋英国）API 生产占全球 64%；按价值或吨位口径未披露，待核。http://staging.efpia.eu/media/fjtncni2/efpia-manufacturing-leaflet-2024.pdf（2026-11 访问）
• B Conlon et al.《Two-step immobilized enzyme conversion of CPC to 7-ACA》Biotechnol Bioeng, 1995：两步双酶摩尔收率 85%。https://analyticalsciencejournals.onlinelibrary.wiley.com/doi/10.1002/bit.260460603（2026-11 访问）
• B Process Development for 6-APA Using Lentikats-Encapsulated E. coli（PMC7675567, 2020）：10 L 中试连续 10 批分离收率 85%–90%。https://pmc.ncbi.nlm.nih.gov/articles/PMC7675567/（2026-11 访问）
• B Practical and Highly Efficient Synthesis of Remdesivir from GS-441524（ACS Omega, 2022）：3 步总收率 76%，原路线 43%。https://pmc.ncbi.nlm.nih.gov/articles/PMC9366944/（2026-11 访问）
• B Progress Toward a Large-Scale Synthesis of Molnupiravir from Cytidine（ACS Omega, 2022）：酶法 2 步 41% 对 17%。https://pubs.acs.org/acsodf/article/6/15/10396/459151/（2026-11 访问）
• B Biocatalytic Synthesis of 7-ADCA with Engineered E. coli Dual Cells（ACS Sustainable Chem Eng, 2025）：15 L 双菌一锅转化率 95.32%。https://pubs.acs.org/doi/full/10.1021/acssuschemeng.4c10421（2026-11 访问）
• B Biocatalytic Asymmetric Synthesis of Chiral Amines Applied to Sitagliptin（Science, 2010）：转氨酶 92%、>99.95% ee。https://www.science.org/cms/asset/0c037f2c-c8ca-42a3-b92f-c197872924a9/pap.pdf（2026-11 访问）
• B Beilstein J Org Chem《Continuous-flow-enabled intensification in nitration processes: a review》：停留时间十分钟级、持液量吨级降至公斤级。https://www.beilstein-journals.org/bjoc/articles/21/132（2026-11 访问）
• B CIRS Group《REACH Registration of Intermediate: Cost Estimation》：1 吨/年登记门槛、SCC 档案 4,000–6,000 / 10,000–30,000 欧元、ECHA 抽查 86% 不满足减免。https://www.cirs-group.com/en（2026-11 访问）
• B 证券时报引中国医药保健品进出口商会／海关：2024 年中国原料药出口 42.98 bn USD、对美 4.52 bn USD。https://stcn.com/article/detail/1639871.html（2026-11 访问）
• C 券商研报：4-AA 由 1,400 元/kg 跌至 700 元/kg（2024 年内），含税与结算口径未披露，待核。https://stock.finance.sina.com.cn/stock/go.php/vReport_Show/kind/lastest/rptid/785439623287/index.phtml（2026-11 访问）
• C NBNNO 供应商技术说明引专利：阿托伐他汀 ATS-8 少 2 步路线 79.5% 对 67.7%，供应商转述、同源对比，待核。https://www.nbinno.com/insights/1134626-atorvastatin-intermediate-green-pharma-supplier（2026-11 访问）
• C 头孢类中间体行业报告：7-ACA 产能 1.32 万吨/年与 2025 年产量 1,286 吨同现、相差一个数量级，口径不自洽，待核；本报告不据此计算开工率或判断中国供给能力。https://www.docin.com/touch_new/preview_new.do?id=4975114932（2026-11 访问）

Key findings

• Reports sharing the name 'pharma intermediates market' cannot be compared directly: six institutions give USD 14.0–187.73 bn, over an order of magnitude apart; four merchant-scope estimates fall in USD 36.60–45.45 bn (a 24% spread explainable within one definition). Anchors are USD 45.45 bn (2025, Mordor) and USD 39.23 bn (2024, SkyQuest). The arithmetic mean of USD 41.23 bn is explicitly discarded — averaging disguises a definition gap as estimation error.
• Technical competition in commodity beta-lactam nuclei is over: 6-APA comes from penicillin G potassium salt in one immobilised acylase hydrolysis step, with 85%–90% isolated yield over 10 consecutive 10 L pilot batches (S25); the two-enzyme route to 7-ACA reached 85% molar yield in 1995 versus about 72% for chemical cleavage (S24). New capacity competes on enzyme lifetime, batch consistency, wastewater load and phenylacetic acid recovery — not on whether to use enzymes.
• Cost steps come from removing steps, not from lifting single-step yield: a new ATS-8 atorvastatin side-chain route uses two fewer steps for 79.5% overall yield versus 67.7% (supplier-relayed patent, grade C, to be verified); remdesivir from GS-441524 takes 3 steps at 76% versus 43% for the original route; enzymatic molnupiravir cuts more than five steps to two at 41% versus 17%. One or two fewer steps also remove solvent types, unit operations and impurity profiles.
• Continuous flow must be judged on two levels: nitration residence times down to minutes, a kilogram-scale electrochemical coupling running 120 hours and AbbVie photoredox at 500 kg show that hazardous single steps are commercial (maturity grade 7). FDA-approved continuous manufacturing, however, sits in drug-product manufacture, with no verifiable end-to-end API case; whole lines remain at pilot scale (no grade, 5–10 years). 'Mature' and 'not yet deployed' both omit the object being assessed.
• Compliance is the gate on capacity and belongs in the quote: China's elimination catalogue lists 12 outdated hazardous process technologies and equipment items (4 processes, 8 equipment types); EU REACH requires registration above 1 tonne/year, with strictly controlled intermediate dossiers costing EUR 4,000–6,000 / 10,000–30,000 by volume band, and 86% of the 400-plus intermediate dossiers sampled by ECHA in 2011 failed the reduced-data conditions. Together with regulatory starting material (RSM) change control, compliance decides whether capacity can legally exist.
• Regions are layered, not substitutes, and precise shares are refused: China exported USD 42.98 bn of APIs in 2024 (an API scope that includes but is not equal to intermediates); India imported USD 4.348 bn of APIs/intermediates in FY2024-25, 73.71% from China; Europe produced 64% of APIs locally (value versus tonnage undisclosed, flagged to be verified). Of 62 data rows, 34 are primary, 24 secondary and 4 unverified. Advanced intermediate capacity has no public verifiable data, so this report constructs no CR4 or HHI.